CN109153677A - Plx3397的盐酸盐晶型及其制备方法和用途 - Google Patents

Plx3397的盐酸盐晶型及其制备方法和用途 Download PDF

Info

Publication number
CN109153677A
CN109153677A CN201780029483.XA CN201780029483A CN109153677A CN 109153677 A CN109153677 A CN 109153677A CN 201780029483 A CN201780029483 A CN 201780029483A CN 109153677 A CN109153677 A CN 109153677A
Authority
CN
China
Prior art keywords
crystal form
plx3397
mono
preparation
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780029483.XA
Other languages
English (en)
Other versions
CN109153677B (zh
Inventor
陈敏华
张炎锋
邹坡
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmaceutical Suzhou Co Ltd
Original Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmaceutical Suzhou Co Ltd filed Critical Crystal Pharmaceutical Suzhou Co Ltd
Publication of CN109153677A publication Critical patent/CN109153677A/zh
Application granted granted Critical
Publication of CN109153677B publication Critical patent/CN109153677B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及PLX3397的盐酸盐晶型及其制备方法和用途。本发明提供的PLX3397的盐酸盐的晶型溶解度更高，粒径更大，有利于后续生产中产品的分离，稳定性良好，特别是机械稳定性更好，为含PLX3397的药物制剂的制备提供了更好的选择，对于药物开发具有非常重要的价值。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201780029483.XA 2016-06-17 2017-06-09 Plx3397的盐酸盐晶型及其制备方法和用途 Expired - Fee Related CN109153677B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610430773 2016-06-17
CN2016104307732 2016-06-17
PCT/CN2017/087711 WO2017215521A1 (zh) 2016-06-17 2017-06-09 Plx3397的盐酸盐晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN109153677A true CN109153677A (zh) 2019-01-04
CN109153677B CN109153677B (zh) 2021-03-12

Family

ID=60663922

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780029483.XA Expired - Fee Related CN109153677B (zh) 2016-06-17 2017-06-09 Plx3397的盐酸盐晶型及其制备方法和用途

Country Status (4)

Country Link
US (1) US10604521B2 (zh)
EP (1) EP3461823B1 (zh)
CN (1) CN109153677B (zh)
WO (1) WO2017215521A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114773336B (zh) * 2022-04-15 2023-12-22 上海皓鸿生物医药科技有限公司 一种游离态plx5622晶型及其制备方法
CN115925700A (zh) * 2022-11-21 2023-04-07 罗欣药业(上海)有限公司 一种酪氨酸激酶抑制剂的晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2016179412A1 (en) * 2015-05-06 2016-11-10 Plexxikon Inc. Synthesis of 1 h-pyrrolo[2,3-b]pyridin derivatives that modulate kinases
WO2016188816A1 (en) * 2015-05-22 2016-12-01 Ucb Biopharma Sprl Treatment of epilepsy
CN107548394A (zh) * 2015-05-06 2018-01-05 普莱希科公司 调节激酶的化合物的固体形式

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101605787A (zh) * 2006-11-22 2009-12-16 普莱希科公司 调节c-fms和/或c-kit活性的化合物及其应用
CN103497188A (zh) * 2006-11-22 2014-01-08 普莱希科公司 调节c-fms和/或c-kit活性的化合物及其应用
WO2016179412A1 (en) * 2015-05-06 2016-11-10 Plexxikon Inc. Synthesis of 1 h-pyrrolo[2,3-b]pyridin derivatives that modulate kinases
CN107548394A (zh) * 2015-05-06 2018-01-05 普莱希科公司 调节激酶的化合物的固体形式
WO2016188816A1 (en) * 2015-05-22 2016-12-01 Ucb Biopharma Sprl Treatment of epilepsy

Also Published As

Publication number Publication date
US10604521B2 (en) 2020-03-31
EP3461823B1 (en) 2020-06-03
WO2017215521A1 (zh) 2017-12-21
EP3461823A1 (en) 2019-04-03
CN109153677B (zh) 2021-03-12
US20190256510A1 (en) 2019-08-22
EP3461823A4 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
WO2016124137A1 (zh) 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
CN104327085A (zh) Pci-32765的晶型a及其制备方法
CN104961671B (zh) N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法
CN109153656A (zh) 他发米帝司葡甲胺盐的晶型e及其制备方法和用途
KR102089254B1 (ko) 아자 2 고리형 화합물의 결정
CN110088088A (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
CN108884111A (zh) 克立硼罗游离形式的晶型及其制备方法和用途
CN105732575A (zh) 一种治疗前列腺癌的新型抗雄激素类药物的新晶型及其制备方法
EP3176173A1 (en) Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
CN105061420B (zh) 一种jak抑制剂的晶型及其制备方法和应用
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN109548403A (zh) Galunisertib的晶型及其制备方法和用途
CN109153677A (zh) Plx3397的盐酸盐晶型及其制备方法和用途
CN110049981A (zh) 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途
Shi et al. Improving physicochemical properties of Ibrutinib with cocrystal strategy based on structures and natures of the carboxylic acid co-formers
Neelam et al. Physicochemical aspects and comparative analysis of Voxelotor and its salt and cocrystal
CN109476662A (zh) 一种jak1选择性抑制剂的新晶型及其制备方法和用途
CN107721902A (zh) 阿普斯特与烟酰胺的共结晶及其制备方法和应用
KR101928987B1 (ko) 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도
CN109153676A (zh) Nbi-98854的晶型及其制备方法和用途
CN110036003A (zh) Ap26113的新晶型及其制备方法
CN110177779A (zh) 一种病毒蛋白抑制剂药物vx-787的晶型及其制备方法和用途
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы
CN114075135B (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
TW201512204A (zh) 埃克替尼磷酸鹽的新晶型及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210312